ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually providing an update on the usage of the “at the market” equity of its providing program.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering system under which Acasti may well issue and sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been offered at prevailing market rates averaging US$1.0747 a share. No securities had been offered through the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with the services of theirs. As a result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and often will supply the Company with additional flexibility in its continuous review process to explore as well as evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety and efficacy in lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements in that press release that aren’t statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, along with other unknown elements that can result in the particular results of Acasti to be materially different from historical success and even as a result of any future outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the particular date of this particular press release. Forward-looking assertions in this press release include, but aren’t limited to, info or statements concerning Acasti’s strategy, future operations and its review of strategic options.
The forward-looking claims contained in this specific press release are expressly qualified in their entirety by this cautionary statement, the “Special Note Regarding Forward-Looking Statements” area in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking claims in this press release exist as of the date of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign some such forward-looking statements whether as a result of info which is new, future events or perhaps otherwise, except as required by law. The forward-looking claims contained herein are also subject typically to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use